



Silva Pharmaceuticals Limited

Utilization of IPO Fund Proceeds

For the month ended 30 October 2024

AUDITORS' REPORT
OR
Utilization of IPO Proceeds

We have audited the annexed Statement of Initial Public Offering (IPO) Proceeds Utilization of Silva Pharmaceuticals Limited for the month ended 31 October 2024 as per required by Bangladesh Securities and Exchange Commission (BSEC) under Section 20C of the Securities and Exchange Ordinance 1969.

Management's Responsibility for the IPO proceeds Utilization

Management is responsible for the preparation and fair presentation of these IPO proceeds utilization statement in accordance with Bangladesh Securities and Exchange Commission Rules 2020, Condition laid down in clause 2, 3, 5 & 6 of PART-C of consent letter # BSEC/CI/IPO-269/2017/429, Dated 28 June 2018 and other applicable laws and regulations.

Auditor's Responsibility

Our responsibility is to express an independent opinion on these Initial Public Offering (IPO) proceeds utilization statement based on our audit. We conducted our audit in accordance with International Standards on Auditing (ISA), Bangladesh Securities and Exchange Commission Rules 2020, Condition laid down in clause 2, 3, 5 & 6 of PART- C of consent letter # BSEC/CI/IPO-269/2017/429, Dated 28 June, 2018 and other applicable laws and regulations.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Qualified Opinion

In our Opinion, except for, Paragraph below "Basis for Qualified Opinion" the Statement of Initial Public Offering (IPO) Proceeds Utilization, prepared in accordance with Bangladesh Securities and Exchange Commission Rules 2020 and Condition laid down in clause 2, 3, 5 of PART- C of consent letter # BSEC/CI/IPO-269/2017/429, Dated 28 June, 2018 and other applicable laws and regulations, gives a true and fair view of the statement for the month 31 October 2024.

Basis for Qualified Opinion

As of August 31, 2024 Total FDR balance was Tk.54,482,929 of IPO Fund including interest thereof in Account # 401253200004347, Shatmasjid Branch, Shahjalal Islamic Bank PLC which was reported monthly with due course. On September 26, 2024 an amount of Tk. 4,482,929.44 had been transferred out of interest of unutilized IPO fund to CD account # 401211100007640 of the same Bank of the company. There appeared a violation of IPO fund utilization without due consent from the appropriate authority.

As per TOR, we draw attention to the following matter:

1. During the month of October 2024, no expenses has been incurred in respect of Civil Construction. However, the company has utilized accumulative amount of Tk. 60,532,650 up to 31 October 2024 which was 104.26% of the amount specified in the prospectus and thereafter revised utilization plan for the purpose of Civil Construction. As such, approval was a pre-requisite from the respected shareholders and concerned regulatory authority for the excess utilized amount of Tk. 2,474,124.
2. During the month of October 2024, no expenses has been incurred in respect of purchase of new Machinery and Equipment's. However, the company has utilized accumulative amount of Tk. 94,317,362 which was 76.99% up to 31 October 2024 in respect of Purchase of Machinery and Equipment's.
3. The Company has utilized Tk. 99,000,000 which was 100% of the budgeted amount up to 31 October 2024 for the purpose of loan repayment as specified in the prospectus.
4. The Company has utilized Tk. 20,441,474 which was 100% of the budgeted amount up to 31 October 2024 for the purpose of IPO expenses as specified in the prospectus and thereafter revised utilization plan.

We also state that:

- a) IPO proceeds have been utilized for the purposes as specified in the prospectus and thereafter revised utilization plan except the above said issues no.1 of the Company;
- b) IPO proceeds have been utilized in so far line with the conditions of the BSEC's consent letter for the IPO except the above said issues no. 1.
- c) The time frame for completion of the utilization of IPO proceeds was revised and will be completed within the time frame as specified in the resolution of 22nd Annual General Meeting (AGM).
- d) Utilization of IPO proceeds is accurate for the purpose of the company as mentioned in the prospectus and 18th AGM of the Company.
- e) Audit statement has been made on verification of all necessary documents/papers/vouchers in support of utilization of IPO proceeds making reconciliation with bank statements.

Dhaka, Bangladesh
Dated: 10 November 2024



Mesbah Uddin FCA

Partner

ICAB Enroll No.: 1533

FRC Enlistment No.: CA-001-177

Pinaki & Company

Chartered Accountants

FRC Firm Enlistment No.: CAF-001-133

**Report on Utilization of IPO Proceeds
 For the Month of October 2024**

Name of the Company: **Silva Pharmaceuticals Limited**
 Amount (BDT) of capital raised through IPO: **BDT 300,000,000**
 Date of Close of Subscription: **05 August 2018**
 Proceeds Receiving Date: **10 October 2018**
 Last Date of Full Utilization of IPO Fund as per Prospectus: **As stated in time line column**

S.L	Purpose mentioned in the prospectus / 18th AGM	Time Line					Amount as per Prospectus	Amount as per 18th AGM	Status of Utilization							Remarks	
		As per Prospectus	As per 18th AGM	As per 19th AGM	As per 21st AGM	As per 22nd AGM			Opening	During the Month	Total Utilized Amount	Utilized %	Excess Utilized amount	Excess-utilized %	Total unutilized amount		Un-utilized %
1	Civil Construction	09.04.2020	09.10.2020	31.12.2022	N/A	N/A	58,000,000	58,058,526	69,532,650	-	69,532,650	104.26	2,474,124	4.26	-	-	
2	Machinery and Equipment	09.04.2020	09.10.2020	31.12.2022	31.12.2023	31.12.2024	122,500,000	122,500,000	94,317,362	-	94,317,362	76.99	-	-	28,182,638	23.01	
3	Repayment of Bank Borrowing at prospectus	08.01.2019	N/A	N/A	N/A	N/A	99,000,000	99,000,000	99,000,000	-	99,000,000	100.00	-	-	-	-	
4	IPO Expenses	N/A	N/A	N/A	N/A	N/A	22,500,000	20,441,474	20,441,474	-	20,441,474	100.00	-	-	-	-	
Total							300,000,000	300,000,000	274,291,486	-	274,291,486	91.43	2,474,124	0.82	28,182,638	9.39	

- Notes:**
- Actual application was received almost 25-76 Times.
 - IPO proceeds have been utilized for the purposes/head as specified in the prospectus and in line with the condition of the Commission's consent letter.
 - Interest on IPO Proceeds in BDT (from FDR & SND) - Net of Charges, Tax and Duties etc.
 - Un-Utilized IPO Proceeds with interest income in BDT -

28,774,415
 50,000,000

Silvana Mirza
Silvana Mirza
 Chairman

Dr. Saira Khan
Dr. Saira Khan
 Managing Director

Md. Abul Kasem
Md. Abul Kasem
 Chief Financial Officer

Md. Hossain
Md. Hossain
 Company Secretary
Mehab Uddin FCA
Mehab Uddin FCA
 Partner
 ICAB Enroll No: 1533
 FRC Enrolment No: CA-001-177
 Pinaki & Company
 Chartered Accountants
 FRC Firm Enrolment No. - CAF-001-133

Dhaka
 Dated: 10 November 2024

Office Address: Ideal Trade Center (9th Floor), 102 Shaheed Tajuddin Ahmed Sarani, Tejgaon, Dhaka-1208, Bangladesh
 Tel : +8802-4101-0592, +8802-4101-0593 & +8802-4101-0594, Cell: +8801711-106302, +8801534-130750
 E-mail: pinaki_co@yahoo.com, info@pinakicbd.com, Website: www.pinakicbd.com